UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043797
Receipt number R000049559
Scientific Title Effect of fermented rice drink containing sake lee on blood cholesterol
Date of disclosure of the study information 2021/03/31
Last modified on 2023/04/05 10:07:45

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of fermented rice drink containing sake lee on blood cholesterol

Acronym

Effect of fermented rice drink containing sake lee on blood cholesterol

Scientific Title

Effect of fermented rice drink containing sake lee on blood cholesterol

Scientific Title:Acronym

Effect of fermented rice drink containing sake lee on blood cholesterol

Region

Japan


Condition

Condition

Healthy volunteers

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the effect of fermented rice drink containing sake lee on serum LDL-cholesterol level.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

12-week changes in serum LDL-cholesterol

Key secondary outcomes

12-week changes in BMI, body fat percentage, abdominal circumference, blood glucose, T-Cho, HDL-Cho, TG, ALT, AST, r-GTP, and fecal bile acid concentration


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Intake of fermented rice drink containing sake lee (190 g/day) for 12 weeks.

Interventions/Control_2

Intake of placebo drink (without fermented rice and sake lee) (190 g/day) for 12 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

120<=LDL-Cho<159

Key exclusion criteria

1) Allergy to fermented rice drink or sake lee
2) In pregnancy or nursing a child
3) Taking medicines or receiving health guidance for hypertension, diabetes, and/or hyperlipidemia
4) Taking drugs or functional food that may affect the body fat percentage and serum cholesterol
5) Taking large volume of fermented rice drink or sake lee habitually
6) Participation in any clinical trial within 90 days of the commencement of the trial

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Masafumi
Middle name
Last name Noda

Organization

Graduate School of Biomedical and Health Sciences
Hiroshima University

Division name

Probiotic Science for Preventive Medicine

Zip code

734-8551

Address

Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, Japan

TEL

082-257-5288

Email

bel@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name Masafumi
Middle name
Last name Noda

Organization

Graduate School of Biomedical and Health Sciences Hiroshima University

Division name

Probiotic Science for Preventive Medicine

Zip code

734-8551

Address

Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, Japan

TEL

082-257-5288

Homepage URL


Email

bel@hiroshima-u.ac.jp


Sponsor or person

Institute

Hiroshima University

Institute

Department

Personal name



Funding Source

Organization

Morinaga & Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee for Clinical Research of Hiroshima University

Address

Kasumi 1-2-3 Minami-ku, Hiroshima 734-8551

Tel

082-257-1551

Email

iryo-seisaku@office.hiroshima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 03 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

40

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 03 Month 10 Day

Date of IRB

2021 Year 03 Month 31 Day

Anticipated trial start date

2021 Year 03 Month 31 Day

Last follow-up date

2021 Year 09 Month 06 Day

Date of closure to data entry

2021 Year 09 Month 08 Day

Date trial data considered complete

2021 Year 10 Month 01 Day

Date analysis concluded

2022 Year 12 Month 31 Day


Other

Other related information

40 participants were already entered.
The data obtained from the present study are now analyzing.


Management information

Registered date

2021 Year 03 Month 31 Day

Last modified on

2023 Year 04 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049559


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name